BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 23376975)

  • 1. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
    Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
    J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
    Hamberg AK; Friberg LE; Hanséus K; Ekman-Joelsson BM; Sunnegårdh J; Jonzon A; Lundell B; Jonsson EN; Wadelius M
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1275-83. PubMed ID: 23307232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.